Product Details

Alunbrig

Brigatinib
90 mg
Tablet


DIN/PIN/NPN

02479214

Manufacturer

Takeda Canada Inc.

Formulary Listing Date

2022-02-10  

Unit Price

336.9643

Amount MOH Pays

336.9643

Coverage Status

Exceptional Access Program Product

ODB Formulary Therapeutic Classification

Therapeutic Note

NO

ATC Code

L01ED04

Interchangeable Products

NO  

LU Clinical Criteria

NO  

EAP Criteria

Therapeutic Class Reimbursement Criteria
Oncology Drugs

Brigatinib

  • Brand(s): Alunbrig
  • Dosage Form/Strength: 30 mg, 90 mg, 180 mg tablet; 7x90 mg and 21x180 mg oral starter kit
  • Effective date: February 10, 2022

Initial Criteria

For the treatment of anaplastic lymphoma kinase (“ALK”) – positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) in patients meeting ALL the following criteria:

  1. 18 years of age or older; AND

  2. Patient has not been treated with another ALK inhibitor for NSCLC; AND

  3. Brigatinib is used as monotherapy; AND

  4. Patient has good performance status.

Exclusion criteria:

  • Brigatinib will not be funded in patients who have experienced disease progression on an ALK inhibitor.
  • Brigatinib will not be funded as combination therapy with another ALK-inhibitor.

Notes:

  1. Patients who have received chemotherapy or radiation therapy should wait 2 weeks before starting brigatinib.
  2. On a time-limited basis, patients who have developed intolerances to crizotinib or alectinib used within a first line setting, and who meet the above criteria, may be considered for a switch to brigatinib on a case-by-case basis. Provide details of the intolerances including the grade of toxicity (as applicable) and reasons for the switch.

Renewal Criteria:
Ongoing funding will be considered in patients who have not experienced disease progression or unacceptable toxicities to treatment with brigatinib.

Recommended dose: Starting dose of 90 mg daily for the first 7 days and, if tolerated, dose increased to 180 mg daily.

Approval duration of initial and renewal requests: 1 year

EAP Drug Request Form:

Standard Form for EAP Drug Requests

Product Monograph

View Monograph